Shukui Qin, MD, PhD
Prof. Dr. Shukui Qin is the Deputy Director of People’s Liberation Army (PLA) 81 Hospital (Nanjing, China), Director of Cancer Center of Chinese PLA, and Director of National Drug Clinical Trial Agency of PLA 81 Hospital. He serves as the Executive Member of the Asian Clinical Oncology Society (ACOS), Chair of Chinese Society of Clinical Oncology (CSCO), Council Member of PLA Medical Science Commission (and the Executive Member of its oncology society), Member of the Oncology Branch of Chinese Medical Association, Expert Committee Member of National Tumor Standardized Diagnosis and Treatment of Ministry of Health (and also the leader of the Liver Cancer Expert Panel and Cancer Pain Expert Panel), Vice President of Beijing Xisike Clinical Oncology Research Foundation, and Member of Chinese Anti-cancer Association (CACA) (and the Vice Chairman of the Committee of Rehabilitation and Palliative Care affiliated to CACA). After decades of clinical practice and scientific research, Dr. Qin has accumulated rich experiences in the medical treatment of gastrointestinal cancers and their bone metastases. Dr Qin has published over 400 articles in peer-reviewed journals and 44 scientific books. He has been granted numbers of professional awards at the ministerial and provincial levels (including four first-class prizes, two second-class prizes,seven third-class prizes, and two fourth-class prizes). He enjoys special allowance from State Council of China and the PLA. Currently he is the Editor-in-Chief of two highly rated journals (Journal of Clinical Oncology and Clinical Oncology Tribune) in China.
Jiade J. Lu, MD, MBA
Dr. Lu obtained his Medical Doctor (M.D.) from the Medical School of the State University of New York at Buffalo, USA, and his M.B.A. from both the University of California, Los Angeles and the National University of Singapore. He completed his residency training in radiation oncology at University of Miami Jackson Memorial Hospital. After his specialty training, Dr. Lu started his academic career at the Department of Radiation Oncology at the National University Cancer Institute of Singapore (NCIS). In 2010, he was appointed the Head of the Department of Radiation Oncology of the National University Hospital/NCIS. In 2012, he was appointed the Vice Chairman of Medical Board of the National University Hospital (Research). In February 2014, he accepted the appointment by the Shanghai Municipal Government, and started his endeavor as the Executive President of the newly established Shanghai Proton and Heavy Ion Center.
Dr. Lu is active in clinical practice as well as academic activity. In addition to his busy clinical and research work in head and neck cancers, he has edited and published 8 oncology texts or reference books, contributed to over 25 book chapters, and close to 100 original articles in international peer-reviewed journals. With the help from his colleagues, Dr. Lu started the Journal of Radiation Oncology in 2012.
Dr. Lu had served a number of international publishing and publicly listed corporations as advisor or independent board member of the board of directors.
M.D. (Medicine) from the State University of New York at Buffalo
M.B.A. from University of California, Los Angeles
M.B.A. from the National University of Singapore
B.S. (Biochemistry) from the State University of New York at Buffalo
Charles M. Balch, MD, FACS
Dr. Balch leads a distinguished career as a surgical oncologist and authority in melanoma and breast cancer. He has authored over 630 publications on topics such as clinical investigations involving the natural history of melanoma, prognostic factors predicting clinical outcomes, standards of surgical treatment, and the conduct and methodology of clinical research and immunology. He is regarded as one of the leading melanoma experts in the world. He is the editor of Cutaneous Melanoma, regarded as the authoritative textbook on melanoma, now in its 5th edition. He is the founding Editor-in-Chief of the Annals of Surgical Oncology and is Chair of the Melanoma Staging Committee of the American Joint Committee on Cancer, which determines the staging criteria for melanomas worldwide. He has held major leadership roles in clinical research in 3 comprehensive cancer centers (UAB, M D Anderson, and City of Hope). He has been a PI or Co-PI of numerous clinical trials, including 10 phase III trials, most of which were NCI-funded National Phase III trials. He has organized or participated in randomized surgical trials that have defined the current standards of melanoma surgery.